XCEEDANCE
3.3.2020 09:02:14 CET | Business Wire | Press release
Xceedance , a global provider of insurance consulting, managed services, technology, data sciences, and blockchain solutions, today launched its life insurance and reinsurance practice and announced the establishment of an office in Liechtenstein to serve life re/insurance markets.
The practice focuses on partnering with existing and start-up life re/insurance organisations and insurtech providers, offering services such as interim management, strategic consulting, product development, actuarial services, sales strategy consulting, Solvency II Pillar 1-2 support, and reinsurance optimisation. In addition, Xceedance can help carriers with legacy transformation to better manage new and existing business, and to transact run-off portfolios.
Markus Brugger and Mark Lucas will jointly direct the newest international office of Xceedance, as leaders of the life insurance and reinsurance sectors respectively.
“Liechtenstein is a significant financial services hub, including for worldwide life re/insurers, and our rapidly growing company is especially skilled in supporting the full range of insurance operations, as we help our global clients gain new business, grow revenues and minimise expenses,” said Arun Balakrishnan, CEO, Xceedance. “We are excited to locate an office in Liechtenstein and expand opportunities for direct interaction with diverse life re/insurance organisations, both in the EMEA region and worldwide.”
“Liechtenstein is a well-established global insurance marketplace, and Xceedance can help and support life re/insurers worldwide to strengthen their operations and enter new markets,” said Markus Brugger.
“We are excited to join a dynamic company such as Xceedance and look forward to building the company’s life re/insurance consulting and technology services to assist the industry in addressing pressing challenges and diverse market opportunities,” said Mark Lucas.
Mr. Brugger has 30 years of life re/insurance experience and was president of the Liechtenstein Insurance Association from 2012 to 2014. He has held senior roles with Winterthur Re, Cologne Re, and PartnerRe, and was CEO for 17 years at PrismaLife and Liechtenstein Life. Mr. Brugger joins Xceedance from Grant Thornton Liechtenstein/Switzerland, where he led the insurance advisory practice.
Mr. Lucas has 35 years of industry experience at Guy Carpenter in Denmark, U.S. Re in Switzerland, and most recently at JLT Re in Switzerland, where he was general manager. Mr. Lucas has developed several new reinsurance products over his career and brings a wealth of life reinsurance knowledge to Xceedance.
About Xceedance
Xceedance (www.xceedance.com ) is a global provider of strategic consulting, actuarial, and managed services, technology, and data sciences to property/casualty and life insurance organisations. Domiciled in Bermuda, with offices in the United States, United Kingdom, Germany, Liechtenstein, Poland, India, and Australia, Xceedance helps re/insurers launch new products, drive operations, implement intelligent technology and blockchain solutions, deploy advanced analytic capabilities, and achieve business process optimisation. The experienced insurance professionals at Xceedance enable re/insurers, brokers, TPAs, agents, and program administrators worldwide to enhance policyholder service, enter new markets, boost workflow productivity, and improve profitability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200303005108/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom